{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:40:02Z","timestamp":1744764002725,"version":"3.40.4"},"reference-count":30,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Brugada syndrome is a rare genetic cardiac abnormality that has been linked to aggravation of arrhythmias and sudden cardiac death through concomitant medication use, including psychotropic medications. This complicates the clinical team\u2019s approach to treatment of depression in patients with Brugada syndrome as many first-line psychotropic agents are recommended to be preferentially avoided. Aripiprazole, which has no formal recommendation for or against use in Brugada syndrome, is approved for augmentation treatment of major depressive disorder therapy. This case report details a male patient with a history of Brugada syndrome who was referred to an intensive outpatient program for worsening of chronic depression. Through a multidisciplinary, shared decision-making approach, aripiprazole was added to the existing regimen of bupropion and duloxetine for augmentation of depression therapy despite minimal evidence in Brugada syndrome. Patient adherence to aripiprazole therapy was reported for approximately 4 weeks with no significant electrocardiogram (ECG) changes compared with baseline. The patient noted subjective improvement in depressive symptoms with the addition of aripiprazole with an objective improvement in Quick Inventory of Depressive Symptomatology total score from moderate-to-mild symptoms. This case report describes 1 of the few cases documenting safe use of aripiprazole to augment depression therapy in a patient with a documented history of Brugada syndrome without potentiating a Brugada-pattern ECG, associated cardiac event, or worsening depression through almost 4 weeks of therapy. More studies regarding the effectiveness and safety of aripiprazole in the augmentation of depression therapy and safety in patients with Brugada syndrome are needed.<\/jats:p>","DOI":"10.9740\/mhc.2025.04.062","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:01:21Z","timestamp":1743811281000},"page":"62-8","source":"Crossref","is-referenced-by-count":0,"title":["A case report on the safety and efficacy of aripiprazole for depression in Brugada syndrome"],"prefix":"10.9740","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-5607","authenticated-orcid":true,"given":"Monica","family":"Fahmy","sequence":"first","affiliation":[{"name":"(Corresponding author) Clinical Pharmacy Specialist, Yale New Haven Hospital, New Haven, Connecticut, monica.fahmy@ynhh.org"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-9099","authenticated-orcid":true,"given":"Youssef","family":"Bessada","sequence":"additional","affiliation":[{"name":"Assistant Clinical Professor, University of Connecticut School of Pharmacy, Storrs, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1229-0194","authenticated-orcid":true,"given":"Cassandra","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Psychiatric Mental Health Nurse Practitioner, Yale New Haven Hospital, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8780-7978","authenticated-orcid":true,"given":"Jennifer R.","family":"Zigun","sequence":"additional","affiliation":[{"name":"Attending Psychiatrist, Adult Ambulatory Services, Yale New Haven Health, Hamden, Connecticut; Assistant Clinical Professor, Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"key":"i2168-9709-15-2-62-b01","article-title":"Depressive disorder (depression)","author":"World Health Organization [Internet].","year":"2023","unstructured":"World Health Organization [Internet]. Depressive disorder (depression). 2023 March 31 [cited 2024 Sept 20]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"i2168-9709-15-2-62-b02","article-title":"Mental health at work","author":"World Health Organization","year":"2024","unstructured":"World Health Organization [Internet]. Mental health at work. 2024 Sept 2 [cited 2024 Sept 20]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-health-at-work"},{"issue":"3","key":"i2168-9709-15-2-62-b03","series-title":"Psychiatry Investig","first-page":"207","article-title":"Understanding the complex of suicide in depression: from research to clinics","volume":"17","author":"Orsolini","year":"2020","unstructured":"Orsolini L,Latini R,Pompili M,Serafini G,Volpe U,Vellante F, et al. Understanding the complex of suicide in depression: from research to clinics. Psychiatry Investig. 2020;17(3):207-21. DOI: 10.30773\/pi.2019.0171"},{"key":"i2168-9709-15-2-62-b04","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association; 2013."},{"issue":"3","key":"i2168-9709-15-2-62-b05","series-title":"Epidemiol Psychiatr Sci","first-page":"210","article-title":"Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys","volume":"24","author":"Kessler","year":"2015","unstructured":"Kessler RC,Sampson NA,Berglund P,Gruber MJ,Al-Hamzawi A,Andrade L, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24(3):210-26. DOI: 10.1017\/S2045796015000189"},{"issue":"Suppl 1","key":"i2168-9709-15-2-62-b06","series-title":"Indian J Psychiatry","first-page":"S34","article-title":"Clinical practice guidelines for the management of depression","volume":"59","author":"Gautam","year":"2017","unstructured":"Gautam S,Jain A,Gautam M,Vahia VN,Grover S. Clinical practice guidelines for the management of depression. Indian J Psychiatry. 2017;59(Suppl 1):S34-50. DOI: 10.4103\/0019-5545.196973"},{"key":"i2168-9709-15-2-62-b07","series-title":"Neuropsychiatr Dis Treat","first-page":"221","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","unstructured":"Voineskos D,Daskalakis ZJ,Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221-34. DOI: 10.2147\/NDT.S198774"},{"issue":"9","key":"i2168-9709-15-2-62-b08","series-title":"Can J Psychiatry","first-page":"641","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults","volume":"69","author":"Lam","year":"2024","unstructured":"Lam RW,Kennedy SH,Adams C,Bahji A,Beaulieu S,Bhat V, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69(9):641-87. DOI: 10.1177\/07067437241245384"},{"issue":"6","key":"i2168-9709-15-2-62-b09","series-title":"J Am Coll Cardiol","first-page":"1391","article-title":"Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report","volume":"20","author":"Brugada","year":"1992","unstructured":"Brugada P,Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20(6):1391-6. DOI: 10.1016\/0735-1097(92)90253-j"},{"issue":"6","key":"i2168-9709-15-2-62-b10","series-title":"Acta Cardiol","first-page":"795","article-title":"The Brugada syndrome","volume":"64","author":"Esc\u00e1rcega","year":"2009","unstructured":"Esc\u00e1rcega RO,Jim\u00e9nez-Hern\u00e1ndez M,Garcia-Carrasco M,Perez-Alva JC,Brugada J. The Brugada syndrome. Acta Cardiol. 2009;64(6):795-801. DOI: 10.2143\/AC.64.6.204474520128157"},{"issue":"9","key":"i2168-9709-15-2-62-b11","series-title":"Heart Rhythm","first-page":"1335","article-title":"Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org)","volume":"6","author":"Postema","year":"2009","unstructured":"Postema PG,Wolpert C,Amin AS,Probst V,Borggrefe M,Roden DM, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6(9):1335-41. DOI: 10.1016\/j.hrthm.2009.07.002"},{"issue":"12","key":"i2168-9709-15-2-62-b12","series-title":"Nat Rev Cardiol","first-page":"744","article-title":"Pathogenesis and management of Brugada syndrome","volume":"13","author":"Sieira","year":"2016","unstructured":"Sieira J,Dendramis G,Brugada P. Pathogenesis and management of Brugada syndrome. Nat Rev Cardiol. 2016;13(12):744-56. DOI: 10.1038\/nrcardio.2016.143"},{"issue":"18","key":"i2168-9709-15-2-62-b13","series-title":"Psychopharmacology (Berl","first-page":"3297","article-title":"The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach","volume":"232","author":"Polcwiartek","year":"2015","unstructured":"Polcwiartek C,Sneider B,Graff C,Taylor D,Meyer J,Kanters JK, et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl). 2015;232(18):3297-308. DOI: 10.1007\/s00213-015-4024-9"},{"issue":"5","key":"i2168-9709-15-2-62-b14","series-title":"Biol Psychiatry","first-page":"573","article-title":"The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","unstructured":"Rush AJ,Trivedi MH,Ibrahim HM,Carmody TJ,Arnow B,Klein DN, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-83. DOI: 10.1016\/s0006-3223(02)01866-8. Erratum in: Biol Psychiatry. 2003;54(5):585."},{"issue":"1","key":"i2168-9709-15-2-62-b15","series-title":"Heart Rhythm","first-page":"33","article-title":"An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing","volume":"7","author":"Kapplinger","year":"2010","unstructured":"Kapplinger JD,Tester DJ,Alders M,Benito B,Berthet M,Brugada J, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7(1):33-46. DOI: 10.1016\/j.hrthm.2009.09.069"},{"issue":"1","key":"i2168-9709-15-2-62-b16","series-title":"Genet Med","first-page":"3","article-title":"Brugada syndrome: clinical and genetic findings","volume":"18","author":"Sarquella-Brugada","year":"2016","unstructured":"Sarquella-Brugada G,Campuzano O,Arbelo E,Brugada J,Brugada R. Brugada syndrome: clinical and genetic findings. Genet Med. 2016;18(1):3-12. DOI: 10.1038\/gim.2015.35"},{"issue":"3","key":"i2168-9709-15-2-62-b17","series-title":"Cardiovasc Res","first-page":"367","article-title":"Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more","volume":"67","author":"Meregalli","year":"2005","unstructured":"Meregalli PG,Wilde AA,Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc Res. 2005;67(3):367-78. DOI: 10.1016\/j.cardiores.2005.03.005"},{"issue":"2","key":"i2168-9709-15-2-62-b18","series-title":"J Membr Biol","first-page":"79","article-title":"Block of persistent late Na+ currents by antidepressant sertraline and paroxetine","volume":"222","author":"Wang","year":"2008","unstructured":"Wang GK,Mitchell J,Wang SY. Block of persistent late Na+ currents by antidepressant sertraline and paroxetine. J Membr Biol. 2008;222(2):79-90. DOI: 10.1007\/s00232-008-9103-y"},{"issue":"14","key":"i2168-9709-15-2-62-b19","series-title":"Heart","first-page":"1165","article-title":"Resolution of Brugada-pattern ECG after withdrawal of the selective serotonin reuptake inhibitor paroxetine","volume":"96","author":"Sawhney","year":"2010","unstructured":"Sawhney V,Thomas G,Webster P,Schilling R. Resolution of Brugada-pattern ECG after withdrawal of the selective serotonin reuptake inhibitor paroxetine. Heart. 2010;96(14):1165-6. DOI: 10.1136\/hrt.2009.184630"},{"issue":"3","key":"i2168-9709-15-2-62-b20","series-title":"Jpn J Pharmacol","first-page":"335","article-title":"Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine","volume":"45","author":"Yokota","year":"1987","unstructured":"Yokota S,Ishikura Y,Ono H. Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine. Jpn J Pharmacol. 1987;45(3):335-42. DOI: 10.1254\/jjp.45.335"},{"issue":"1","key":"i2168-9709-15-2-62-b21","series-title":"J Cardiovasc Electrophysiol","first-page":"61","article-title":"Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome","volume":"12","author":"Rouleau","year":"2001","unstructured":"Rouleau F,Asfar P,Boulet S,Dube L,Dupuis JM,Alquier P, et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12(1):61-5. DOI: 10.1046\/j.1540-8167.2001.00061.x"},{"issue":"1","key":"i2168-9709-15-2-62-b22","series-title":"Naunyn Schmiedebergs Arch Pharmacol","first-page":"67","article-title":"Electrophysiological effects of fluoxetine in mammalian cardiac tissues","volume":"361","author":"Pacher","year":"2000","unstructured":"Pacher P,Magyar J,Szigligeti P,B\u00e1ny\u00e1sz T,Pankucsi C,Korom Z, et al. Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol. 2000;361(1):67-73. DOI: 10.1007\/s002109900154"},{"issue":"4","key":"i2168-9709-15-2-62-b23","series-title":"Mol Pharmacol","first-page":"378","article-title":"Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics","volume":"86","author":"Poulin","year":"2014","unstructured":"Poulin H,Bruhova I,Timour Q,Theriault O,Beaulieu JM,Frassati D, et al. Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics. Mol Pharmacol. 2014;86(4):378-89. DOI: 10.1124\/mol.114.093104"},{"issue":"11","key":"i2168-9709-15-2-62-b24","series-title":"Mayo Clin Proc","first-page":"1584","article-title":"Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope","volume":"89","author":"Alampay","year":"2014","unstructured":"Alampay MM,Haigney MC,Flanagan MC,Perito RM,Love KM,Grammer GG. Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope. Mayo Clin Proc. 2014;89(11):1584-7. DOI: 10.1016\/j.mayocp.2014.08.010"},{"issue":"5","key":"i2168-9709-15-2-62-b25","series-title":"Fundam Clin Pharmacol","first-page":"599","article-title":"QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile","volume":"26","author":"Caillier","year":"2012","unstructured":"Caillier B,Pilote S,Castonguay A,Patoine D,M\u00e9nard-Desrosiers V,Vigneault P, et al. QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile. Fundam Clin Pharmacol. 2012;26(5):599-608. DOI: 10.1111\/j.1472-8206.2011.00953.x"},{"issue":"9","key":"i2168-9709-15-2-62-b26","series-title":"Rev Esp Cardiol (Engl Ed)","first-page":"856","article-title":"Brugada electrocardiogram pattern induced by cannabis","volume":"65","author":"Romero-Puche","year":"2012","unstructured":"Romero-Puche AJ,Trigueros-Ruiz N,Cerd\u00e1n-S\u00e1nchez MC,P\u00e9rez-Lorente F,Rold\u00e1n D,Vicente-Vera T. Brugada electrocardiogram pattern induced by cannabis. Rev Esp Cardiol (Engl Ed). 2012;65(9):856-8. DOI: 10.1016\/j.recesp.2012.01.01322542484"},{"issue":"6","key":"i2168-9709-15-2-62-b27","series-title":"Cureus","first-page":"e8615","article-title":"Cannabinoid-induced Brugada syndrome: a case report","volume":"12","author":"Stockholm","year":"2020","unstructured":"Stockholm SC,Rosenblum A,Byrd A,Mery-Fernandez E,Bhandari M. Cannabinoid-induced Brugada syndrome: a case report. Cureus. 2020;12(6):e8615. DOI: 10.7759\/cureus.8615"},{"issue":"3","key":"i2168-9709-15-2-62-b28","series-title":"Expert Opin Pharmacother","first-page":"421","article-title":"Vortioxetine: a new treatment for major depressive disorder","volume":"17","author":"Connolly","year":"2016","unstructured":"Connolly KR,Thase ME. Vortioxetine: a new treatment for major depressive disorder. Expert Opin Pharmacother. 2016;17(3):421-31. DOI: 10.1517\/14656566.2016.1133588"},{"issue":"3","key":"i2168-9709-15-2-62-b29","series-title":"Int Clin Psychopharmacol","first-page":"138","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","unstructured":"Boulenger JP,Loft H,Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138-49. DOI: 10.1097\/YIC.0000000000000018"},{"issue":"21","key":"i2168-9709-15-2-62-b30","series-title":"Int J Mol Sci","first-page":"12890","article-title":"Block of voltage-gated sodium channels by aripiprazole in a state-dependent manner","volume":"23","author":"F\u00f6hr","year":"2022","unstructured":"F\u00f6hr KJ,Rapp M,Fauler M,Zimmer T,Jungwirth B,Messerer DAC. Block of voltage-gated sodium channels by aripiprazole in a state-dependent manner. Int J Mol Sci. 2022;23(21):12890. DOI: 10.3390\/ijms23211289"}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/2\/article-p62.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/2\/article-p62.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/2\/article-p62.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:02:02Z","timestamp":1744761722000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/2\/article-p62.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":30,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2025.04.062","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}